Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

4D Molecular Therapeutics (FDMT) Leases (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Leases for 5 consecutive years, with $18.1 million as the latest value for Q4 2025.

  • Quarterly Leases fell 13.91% to $18.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.1 million through Dec 2025, down 13.91% year-over-year, with the annual reading at $18.1 million for FY2025, 13.91% down from the prior year.
  • Leases for Q4 2025 was $18.1 million at 4D Molecular Therapeutics, down from $18.9 million in the prior quarter.
  • The five-year high for Leases was $21.8 million in Q3 2024, with the low at $10.7 million in Q2 2024.
  • Average Leases over 5 years is $15.3 million, with a median of $13.8 million recorded in 2022.
  • Peak annual rise in Leases hit 83.84% in 2025, while the deepest fall reached 13.91% in 2025.
  • Over 5 years, Leases stood at $14.6 million in 2021, then decreased by 10.14% to $13.1 million in 2022, then fell by 11.82% to $11.5 million in 2023, then soared by 82.63% to $21.1 million in 2024, then dropped by 13.91% to $18.1 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $18.1 million, $18.9 million, and $19.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.